Amoy Diagnostics Co. Ltd.

In News

Sinopharm Acquires AmoyDx for 1.65 Billion Yuan, Expanding State-Owned Pharma Empire - finance.biggo.com

finance.biggo.com - Jun 05, 2026

Sinopharm Group to Acquire 20% Stake in Adicon for RMB 1.6 Billion, with Five-Year Share Lock-Up and Control Over Board Renewal | Quick Read Announcement - 富途牛牛

富途牛牛 - Jun 04, 2026

Amoy Diagnostics' 2025 Annual Report Sparks Concern as Dual Versions Show Major Core Data Discrepancies - finance.biggo.com

finance.biggo.com - Apr 30, 2026

AmoyDx® Pan Lung Cancer PCR Panel approved in Japan as a companion diagnostic for Haiyitan® tablets (gumarontinib) - News-Medical

News-Medical - Aug 23, 2024

Comparison of diagnostic performance between Oncomine Dx target test and AmoyDx panel for detecting actionable mutations in lung cancer - Nature

Nature - May 30, 2024

Application of NGS molecular classification in the diagnosis of endometrial carcinoma: A supplement to traditional pathological diagnosis - Rao - 2023 - Cancer Medicine - Wiley Online Library

Wiley Online Library - Nov 07, 2022

Med-tech of China gaining popularity - China Daily Global Edition

China Daily Global Edition - May 15, 2024

Companion Diagnostics Market size is set to grow by USD 28.98 billion from 2024-2028, Rising use of personalized medicine to boost the market growth, Technavio - PR Newswire

PR Newswire - Aug 08, 2024

Next Generation Sequencing Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 - Global Data

Global Data - Jun 21, 2023

Breaking News! Two High-Performing Stocks Clarify Relationship with NVIDIA and Issue Risk Warnings | After-Hours Announcement Roundup - 富途牛牛

富途牛牛 - May 31, 2026

Simulation analysis of EGFR mutation detection: Oncomine Dx target test and AmoyDx panel impact on lung cancer treatment decisions - Nature

Nature - Jan 18, 2024

300633 Stock Price and Chart — SZSE:300633 - TradingView

TradingView - Dec 30, 2017

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment